Syndax Pharmaceuticals, Inc. (SNDX) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 35.74
30Y Low35.7·High35.7
P/FCF
N/A
—
5yr avg: 39.30
30Y Low39.3·High39.3
P/B Ratio
↑
27.53
↑+236% vs avg
5yr avg: 8.19
30Y Low1.2·High28.2
ROE
↓
-161.8%
↑-165% vs avg
5yr avg: -61.0%
30Y Low-162%·High8%
Debt/EBITDA
N/A
—
5yr avg: 0.80
30Y Low0.8·High0.8
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SNDX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Syndax Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.8B | $1.1B | $1.5B | $1.5B | $1.1B | $919M | $268M | $113M | $184M | $105M |
| Enterprise Value | $2.0B | $2.0B | $1.3B | $1.2B | $1.5B | $939M | $824M | $244M | $79M | $149M | $81M |
| P/E Ratio → | -6.24 | — | — | — | — | 45.60 | — | — | — | — | — |
| P/S Ratio | 10.51 | 10.56 | 47.80 | — | — | 8.16 | 605.60 | 176.47 | 74.43 | 87.26 | 85.92 |
| P/B Ratio | 27.53 | 28.16 | 3.93 | 2.74 | 3.31 | 2.79 | 3.64 | 8.47 | 2.13 | 1.76 | 1.25 |
| P/FCF | — | — | — | — | — | 39.30 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 39.12 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SNDX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.79 | 55.89 | — | — | 6.72 | 543.17 | 160.84 | 52.16 | 70.57 | 66.38 |
| EV / EBITDA | — | — | — | — | — | 35.74 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 34.99 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 32.37 | — | — | — | — | — |
SNDX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Syndax Pharmaceuticals, Inc. earns an operating margin of -158.4%. Operating margins have expanded from -1434.4% to -158.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -161.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.0% | 96.0% | 96.5% | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -158.4% | -158.4% | -1434.4% | — | — | 18.8% | -4708.2% | -3792.9% | -5001.7% | -2939.0% | -3587.4% |
| Net Profit Margin | -165.6% | -165.6% | -1346.1% | — | — | 17.8% | -4816.7% | -3688.5% | -4875.5% | -2884.3% | -3645.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -161.8% | -161.8% | -75.7% | -41.0% | -34.1% | 7.5% | -51.5% | -132.2% | -94.0% | -64.5% | -59.0% |
| ROA | -45.5% | -45.5% | -47.7% | -37.7% | -31.5% | 6.6% | -40.1% | -75.9% | -66.9% | -49.4% | -44.7% |
| ROIC | -54.2% | -54.2% | -68.8% | -52.7% | -37.8% | 10.8% | -64.8% | -317.7% | -128.7% | -71.8% | -63.2% |
| ROCE | -53.0% | -53.0% | -57.8% | -45.0% | -33.8% | 7.4% | -43.7% | -101.8% | -80.2% | -56.3% | -47.6% |
SNDX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $212M ($346M total debt minus $135M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.36 | 5.36 | 1.20 | 0.00 | 0.00 | 0.05 | 0.08 | 0.03 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.80 | — | — | — | — | — |
| Net Debt / Equity | — | 3.27 | 0.67 | -0.53 | -0.16 | -0.49 | -0.38 | -0.75 | -0.64 | -0.34 | -0.28 |
| Net Debt / EBITDA | — | — | — | — | — | -7.65 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -6.93 | — | — | — | — | — |
| Interest Coverage | -7.45 | -7.45 | -63.67 | -1005.54 | -46.61 | 14.13 | -30.04 | — | -38.08 | -43.60 | -45.78 |
SNDX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Syndax Pharmaceuticals, Inc.'s current ratio of 4.40x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.00x to 4.40x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.40 | 4.40 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.18 | 8.45 | 10.47 |
| Quick Ratio | 4.12 | 4.12 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.11 | 8.54 | 10.24 |
| Cash Ratio | 3.28 | 3.28 | 5.63 | 9.94 | 16.67 | 21.60 | 15.53 | 3.25 | 5.02 | 8.23 | 10.16 |
| Asset Turnover | — | 0.33 | 0.03 | — | — | 0.31 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 |
| Inventory Turnover | 0.21 | 0.21 | 2.26 | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 80.47 | 213.81 | — | — | 1.12 | 42.11 | 27.91 | 60.87 | 65.28 | 91.55 |
SNDX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Syndax Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | 2.5% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 2.2% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 2.5% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.5% |
| Shares Outstanding | — | $87M | $86M | $70M | $61M | $52M | $41M | $30M | $25M | $21M | $15M |
Peer Comparison
Compare SNDX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SNDXYou | $2B | -6.2 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RVMD | $30B | -24.0 | — | — | — | — | -58.1% | -54.3% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 VERA | $3B | -7.7 | — | — | — | — | -50.7% | -54.6% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
See SNDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNDX vs KYMR
Side-by-side business, growth, and profitability comparison vs Kymera Therapeutics, Inc..
Start ComparisonSNDX — Frequently Asked Questions
Quick answers to the most common questions about buying SNDX stock.
What is Syndax Pharmaceuticals, Inc.'s P/E ratio?
Syndax Pharmaceuticals, Inc.'s current P/E ratio is -6.2x. The historical average is 45.6x.
What is Syndax Pharmaceuticals, Inc.'s ROE?
Syndax Pharmaceuticals, Inc.'s return on equity (ROE) is -161.8%. The historical average is -75.4%.
Is SNDX stock overvalued?
Based on historical data, Syndax Pharmaceuticals, Inc. is trading at a P/E of -6.2x. Compare with industry peers and growth rates for a complete picture.
What are Syndax Pharmaceuticals, Inc.'s profit margins?
Syndax Pharmaceuticals, Inc. has 96.0% gross margin and -158.4% operating margin.